Navigation Links
GeNO LLC Initiates Phase 2 Trial For Nitric Oxide Delivery System
Date:12/8/2010

ward in our plans for these novel technologies, Phase 2 testing of the NITROSYL systems in patients is an important milestone for GeNO," said GeNO LLC Founder and President David Fine. "As a clinical-stage organization, this trial not only moves the in-hospital solution forward but also enables us to move our other exciting, patent-protected technologies, such as the GeNO Ambulatory NITROSYL System, towards clinical development as well."

Robert F. Roscigno, PhD, Vice President of GeNO, commented, "We believe that this System offers the potential to provide PAH patients, as well as the clinicians that treat them, with a safe and effective diagnostic agent. We look forward to seeing the results of this study, and also to filing additional INDs and completing acute and chronic treatment studies. There is a well-established body of clinical evidence suggesting clinical benefit on the use of inhaled nitric oxide for patients with a variety of serious diseases, and the GeNO NITROSYL Systems would add a valuable option for clinicians treating these difficult conditions.  GeNO's system would help address cost, complexity and the lack of portability of current treatment regimens and potentially reach a much larger group of patients."

The next version of GeNO's platform to enter the clinic later this year will be the GeNO Ambulatory NITROSYL System, which is a hand-held unit with a disposable liquid source.  This portable unit snaps into a small, battery operated pump module attaching to a hip or arm holster and provides up to a 4-day continuous supply of inhaled nitric oxide for chronic use.  The simplicity and ease-of-use this system has the potential to greatly expand the use of inhaled nitric oxide to many new chronic indications.  

ABOUT GeNO LLC

GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovativ
'/>"/>

SOURCE GeNO LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SPECTRAL INITIATES U.S. PIVOTAL TRIAL OF TORAYMYXIN™ IN SEPTIC SHOCK
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... and CINCINNATI , ... plc (LSE: SHP, NASDAQ: SHPG ) and ... three-year, broad research collaboration for rare diseases. The goal ... novel therapies to treat rare diseases with high ... capabilities with Cincinnati Children,s research expertise. As a ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, ... at Align Technology, on “ Conducting Postmarket Registries - ... Global Conference and Exhibition on April 25th through April ... the poster presentation, Ale Gicqueau and Victor Chen will ... Registry, the requirements and resources to conduct the registry, ...
(Date:3/25/2015)... , March 25, 2015 Optimal Research, LLC ... Industry Excellence (ViE) Award "Best Clinical Site or Trial ... that Optimal has been selected as a nominee in ... receiving a "Highly Recommended" distinction in 2014. The ViE ... the efforts, accomplishments, and positive contributions of companies and ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2
... new market research report is available in its catalogue: , ... Global Nucleic Acid Testing Industry , , ... , , ... US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The ...
... , ... with Key Partners Recognized , ... Wilmington, Del. (Vocus) June 22, 2010 -- All three DuPont biofuels collaborations ... The DuPont Danisco Cellulosic Ethanol ( DDCE ) joint venture and the DuPont ...
... ... , ... 2010 -- iCardiac Technologies, Inc. , a provider of next generation cardiac core ... selected iCardiac as a preferred vendor. iCardiac will provide a full range of ...
Cached Biology Technology:Reportlinker Adds Global Nucleic Acid Testing Industry 2Reportlinker Adds Global Nucleic Acid Testing Industry 3Reportlinker Adds Global Nucleic Acid Testing Industry 4Reportlinker Adds Global Nucleic Acid Testing Industry 5Reportlinker Adds Global Nucleic Acid Testing Industry 6Reportlinker Adds Global Nucleic Acid Testing Industry 7Reportlinker Adds Global Nucleic Acid Testing Industry 8Reportlinker Adds Global Nucleic Acid Testing Industry 9Reportlinker Adds Global Nucleic Acid Testing Industry 10DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 2DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 3DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303 4Three Top 20 Pharmaceutical Companies Select iCardiac as Preferred Vendor 2
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/12/2015)... March 12, 2015 IriTech, a leading iris ... of the Texas Instruments Design Network, announced today that ... demonstrated its IriShield USB MK2120U device during a launching ... pension distribution. The iris scanner is ... marketed in India through its ...
(Date:3/11/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ... Control Market by Product, Application & By Geography - ... their offering. , This report predicts that ... billion by 2020, with an estimated CAGR of 10.6%. ... products types such as contact cards & readers, contactless ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... , , , , , ... AUDIO: When men outnumber women, the women tend to marry younger and men engage in riskier, ... , , , , , , ... , , , , , , , ANN ARBOR, Mich..---When men outnumber women, ...
... molecule known to be involved in progressive heart failure ... damage after a heart attack, according to researchers at ... conclusion, the research team used gene therapy to inhibit ... kinase 2 (GRK2), and found heart muscles cells in ...
... to grab a glass of milk when you,re on diet, suggests ... Nutrition . In a 2-year weight loss study, milk drinkers had ... that adults who drank the most milk (nearly 2 glasses per ... lost more weight after 2 years than those who had little ...
Cached Biology News:Women: Hope to marry young? Head to Alaska, steer clear of Alabama 2Women: Hope to marry young? Head to Alaska, steer clear of Alabama 3Women: Hope to marry young? Head to Alaska, steer clear of Alabama 4Molecule involved in heart failure now implicated in heart attack damage 2New study finds milk drinkers may have a healthy weight advantage 2
Goat polyclonal to DDDDK tag (FITC) ( Abpromise for all tested applications)....
...
DNA fragmentation factor & Inhibitor of CAD...
Component in MasterPure™ Purification Kits...
Biology Products: